Repare Therapeutics (NASDAQ:RPTX – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a research note issued to investors on Thursday, Benzinga reports. They presently have a $10.00 price target on the stock. HC Wainwright’s target price would suggest a potential upside of 187.36% from the stock’s previous close.
Separately, Lifesci Capital raised shares of Repare Therapeutics to a “strong-buy” rating in a report on Monday, July 29th.
Get Our Latest Analysis on RPTX
Repare Therapeutics Price Performance
Repare Therapeutics (NASDAQ:RPTX – Get Free Report) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.82) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.85) by $0.03. The firm had revenue of $1.07 million during the quarter, compared to analysts’ expectations of $4.02 million. Repare Therapeutics had a negative return on equity of 31.11% and a negative net margin of 99.76%. As a group, equities research analysts expect that Repare Therapeutics will post -2.15 earnings per share for the current year.
Institutional Investors Weigh In On Repare Therapeutics
Hedge funds have recently modified their holdings of the company. Vontobel Holding Ltd. increased its stake in shares of Repare Therapeutics by 20.0% in the 3rd quarter. Vontobel Holding Ltd. now owns 24,000 shares of the company’s stock valued at $83,000 after purchasing an additional 4,000 shares in the last quarter. XTX Topco Ltd acquired a new stake in Repare Therapeutics in the second quarter valued at approximately $110,000. Exchange Traded Concepts LLC increased its position in shares of Repare Therapeutics by 21.2% in the third quarter. Exchange Traded Concepts LLC now owns 50,441 shares of the company’s stock valued at $174,000 after buying an additional 8,809 shares in the last quarter. Marshall Wace LLP acquired a new position in shares of Repare Therapeutics during the 2nd quarter worth approximately $273,000. Finally, Opaleye Management Inc. purchased a new position in shares of Repare Therapeutics during the 1st quarter valued at approximately $318,000. 85.09% of the stock is owned by hedge funds and other institutional investors.
About Repare Therapeutics
Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.
Featured Stories
- Five stocks we like better than Repare Therapeutics
- How to Invest in the FAANG Stocks
- Texas Roadhouse Stock Steering for New Highs This Year
- What is the S&P/TSX Index?
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- What is Insider Trading? What You Can Learn from Insider Trading
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Repare Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repare Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.